Syndax Pharmaceuticals (SNDX) Raw Materials (2025 - 2026)
Syndax Pharmaceuticals' (SNDX) quarterly Raw Materials came in at $30.7 million in Q1 2026, up 1661.04% year-on-year from $1.7 million in Q1 2025, and up 5.75% quarter-over-quarter from $29.0 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Raw Materials (2025 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Raw Materials history runs 2 years deep, the most recent figure standing at $30.7 million for Q1 2026.
- On a quarterly basis, Raw Materials rose 1661.04% year-over-year to $30.7 million in Q1 2026; TTM through Mar 2026 was $30.7 million, a 1661.04% increase from a year earlier, with the FY2025 full-year figure at $29.0 million, changed N/A from the prior year.
- Raw Materials improved to $30.7 million in Q1 2026 per SNDX's latest filing, from $29.0 million in the prior quarter.
- Across five years, Raw Materials topped out at $30.7 million in Q1 2026 and bottomed at $1.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.87 Bn | 1.52 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.70 Mn |
| Dec 31, 2025 | 29.03 Mn |
| Sep 30, 2025 | 21.40 Mn |
| Jun 30, 2025 | 14.18 Mn |
| Mar 31, 2025 | 1.74 Mn |